ASLAN Pharmaceuticals Ltd. (ASLN) skyrocketed 160.8% on Mar 11 due to encouraging preliminary data reaffirming the potential of its investigational candidate, eblasakimab, to effectively treat atopic dermatitis (AD, also called eczema) patients. The intended patient population includes those previously treated with Sanofi (SNY) and Regeneron’s (REGN) blockbuster drug Dupixent (dupilumab).Eblasakimab, a novel monoclonal antibody, is an inhibitor of the IL-13 receptor sub-unit of the Type 2 receptor, which is ...